Abstract:To assess the current status in dyslipidemia management in China.We recruited 2306 patients who received lipid-lowering drugs between January 1, 2004 and February 28, 2006, and maintained on the treatment for at least 2 months, from 21 provincial level hospitals and 6 prefecture and country level hospitals. The goal attainment rate was defined as the percentage of patients reaching cholesterol goals recommended by the updated Adult Treatment Panel III (ATPIII) of the National Cholesterol Education Program and the new Chinese Guidelines on Prevention and Treatment of Dyslipidemia in Adults.(1) Among 2094 patients who met guidelines' criteria for initiating drug therapy, there were 80% patients treated in provincial level hospitals, 60% aged 60 years and above, 57% hyperlipidemia, 15% with normal lipids values, 68% coronary heart disease and other atherosclerotic diseases, 75% hypertensive, 80% high or very high risk patients, 84% statin-users and 83% referred to diet change. (2) According to ATPIII 2004, overall 34% patients attained the LDL-C goal. The goal attainment rates was 85%, 78%, 61%, 31% and 22% for patients at low risk, moderate, moderate high, high and very high risk respectively (P for trends < 0.001). According to the new Chinese guidelines, the goal attainment rate was 50% for overall patients and was 91%, 77%, 49% and 38% for patients at low risk, moderate, high and very high risk respectively (P for trend < 0.001). (3) The goal attainment rate was 51% for patients using combination therapy, 35% for those using statins, 23% for those using fibrates, 24% for those using niacin, 28% for those using other lipid-lowering medications (P < 0.001). (4) Among 1808 patients treated with statins, a multi-variable Logistic regression analysis showed that the dosage of statins (high vs. low dose, OR = 1.72, 95% CI: 1.15 - 2.58), risk of patients (very high vs. low risk, OR = 0.02, 95% CI: 0.01 - 0.03), baseline LDL-C [every 0.259 mmol/L (10 mg/dl) increase, OR = 0.83, 95% CI: 0.80 - 0.86] and sex (women vs. men, OR = 0.77, 95% CI: 0.60 - 0.99) were major factors that affected goal attainment.The characteristics of target patients taking lipid-lowering drugs have changed significantly in China and were used not only for lipid lowering but also for other purposes, which is well in accordance with current guidelines. However, current clinical management of dyslipidemia in China is still far behind the desirable goals derived both Chinese guidelines and the updated ATPIII guidelines, especially for high and very high risk patients. To further improve the clinical management of dyslipidemia, it is necessary to strengthen the choice of drugs and dosage, new drug development to allow better and safer combination therapy, intensive therapeutic lifestyle changes, patient health education, etc.

The Impact of Changes in Population LDL-C Levels on LDL-C Control in Patients After PCI in China: A Retrospective Cohort Study

Lower Baseline LDL Cholesterol Affects All-cause Mortality in Patients with First Percutaneous Coronary Intervention.

Atorvastatin Decreased Low Density Lipoprotein Level and Improved Coronary Artery Lesion in Patients after Percutaneous Coronary Intervention

Treatments Prior to and Post Percutaneous Coronary Intervention (PCI) in China

Trends in Percutaneous Coronary Intervention in China: Analysis of China PCI Registry Data from 2010 to 2018

Low LDL-C Levels Are Associated with Risk of Mortality in a Chinese Cohort Study

[Control Rate of Increased Low-Density Lipoprotein Cholesterol Levels in Cardiology Outpatients with Coronary Heart Disease in Beijing].

Achievement of Low-Density Lipoprotein Cholesterol Targets in Chinese Patients with Atherosclerotic Cardiovascular Disease after Receiving Statins and Ezetimibe

Contemporary Management And Attainment Of Cholesterol Targets For Patients With Dyslipidemia In China

HDL-C, Longitudinal Change and Risk of Mortality in a Chinese Cohort Study.

Post-treatment level of LDL cholesterol and all-cause mortality in patients with atherosclerotic cardiovascular disease: evidence from real-world setting

Clinical Outcomes Based on the Attainment of Low-Density Lipoprotein Cholesterol Targets in Patients with Acute Coronary Syndrome in Real-World Practice

Influence of LDL-Cholesterol Lowering on Coronary Plaque Progression of Non-Target Lesions in Patients Undergoing Percutaneous Coronary Intervention: Findings from a Retrospective Study.

Uncontrolled Hyperlipidemia in Chinese Patients Who Experienced Acute Coronary Syndrome: an Observational Study

LDL-cholesterol Goal Attainment under Persistent Lipid-Lowering Therapy in Northeast China

Association and its population heterogeneities between low-density lipoprotein cholesterol and all-cause and cardiovascular mortality: A population-based cohort study

The Gender Differences In Baseline Characteristics And Statin Intervention Among Outpatients With Coronary Heart Disease In China: The China Cholesterol Education Program

A V-shaped association between high-density lipoprotein cholesterol levels and poor outcomes in patients after percutaneous coronary intervention

Real World Effectiveness Of Pcsk-9 Inhibitors Combined With Statins Versus Statins-Based Therapy Among Patients With Very High Risk Of Atherosclerotic Cardiovascular Disease In China (Rwe-Pcsk Study)

Recent trends of low-density lipoprotein cholesterol control and lipid-lowering therapy in patients with atherosclerotic cardiovascular disease in Taiwan: 2015-2020

The second multi-center survey of dyslipidemia management in China: goal attainment rate and related factors]